<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Neumora Therapeutics, Inc. — News on 6ix</title>
<link>https://6ix.com/company/neumora-therapeutics-inc</link>
<description>Latest news and press releases for Neumora Therapeutics, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 06 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/neumora-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a28778dffbe2df109c44.webp</url>
<title>Neumora Therapeutics, Inc.</title>
<link>https://6ix.com/company/neumora-therapeutics-inc</link>
</image>
<item>
<title>Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/neumora-therapeutics-inc/news/neumora-therapeutics-to-participate-in-25th-annual-needham-virtual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/neumora-therapeutics-inc/news/neumora-therapeutics-to-participate-in-25th-annual-needham-virtual-healthcare-conference</guid>
<pubDate>Mon, 06 Apr 2026 11:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 10:15 a.m. ET. A live webcast of the fireside chat will be av</description>
</item>
<item>
<title>Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/neumora-therapeutics-inc/news/neumora-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/neumora-therapeutics-inc/news/neumora-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>New data for NMRA-511 supports unsurpassed clinical effect in a pre-specified population comparable to Rexulti and Auvelity pivotal studies KOASTAL-2 and -3</description>
</item>
<item>
<title>Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026</title>
<link>https://6ix.com/company/neumora-therapeutics-inc/news/neumora-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-on-monday-march-30-2026</link>
<guid isPermaLink="true">https://6ix.com/company/neumora-therapeutics-inc/news/neumora-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-on-monday-march-30-2026</guid>
<pubDate>Mon, 16 Mar 2026 04:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics</description>
</item>
<item>
<title>Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026</title>
<link>https://6ix.com/company/neumora-therapeutics-inc/news/neumora-therapeutics-participate-guggenheim-emerging-120000752</link>
<guid isPermaLink="true">https://6ix.com/company/neumora-therapeutics-inc/news/neumora-therapeutics-participate-guggenheim-emerging-120000752</guid>
<pubDate>Wed, 04 Feb 2026 12:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 4:00 p.m. ET in New York, NY. A live webcast of the fires</description>
</item>
<item>
<title>Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones</title>
<link>https://6ix.com/company/neumora-therapeutics-inc/news/neumora-therapeutics-highlights-2026-pipeline-113500702</link>
<guid isPermaLink="true">https://6ix.com/company/neumora-therapeutics-inc/news/neumora-therapeutics-highlights-2026-pipeline-113500702</guid>
<pubDate>Mon, 05 Jan 2026 11:35:00 GMT</pubDate>
<description>Multiple clinical data readouts expected in 2026 present opportunity for substantial value creation KOASTAL-2 and -3 on track for consolidated topline readout in the second quarter of 2026 Plans to conduct NMRA-215 clinical program in 2026 following class-leading preclinical data from diet induced obesity model Advancing NMRA-511 following Phase 1b results demonstrating clinically meaningful effect on CMAI total score Cash, cash equivalents and marketable securities expected to support operation</description>
</item>
<item>
<title>Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer’s Disease Agitation</title>
<link>https://6ix.com/company/neumora-therapeutics-inc/news/neumora-therapeutics-announces-positive-results-113000900</link>
<guid isPermaLink="true">https://6ix.com/company/neumora-therapeutics-inc/news/neumora-therapeutics-announces-positive-results-113000900</guid>
<pubDate>Mon, 05 Jan 2026 11:30:00 GMT</pubDate>
<description>NMRA-511 demonstrated a 15.7 reduction on mean CMAI total score, representing a clinically meaningful effect NMRA-511 demonstrated unsurpassed clinical effect size on CMAI total score in a pre-specified population with elevated anxiety NMRA-511 demonstrated a favorable tolerability and safety profile Neumora plans to evaluate higher doses of NMRA-511 via initiation of a multiple ascending dose expansion cohort in 2026 Company to host conference call today at 8:00 am ET WATERTOWN, Mass., Jan. 05,</description>
</item>
<item>
<title>Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/neumora-therapeutics-inc/news/neumora-therapeutics-reports-third-quarter-120000556</link>
<guid isPermaLink="true">https://6ix.com/company/neumora-therapeutics-inc/news/neumora-therapeutics-reports-third-quarter-120000556</guid>
<pubDate>Thu, 06 Nov 2025 12:00:00 GMT</pubDate>
<description>Announced class-leading data from diet-induced obesity (DIO) mouse model with NMRA-215, a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor, and expect to initiate Phase 1 study in first quarter of 2026 Advancing Phase 1 studies with two potentially best-in-class positive allosteric modulators (PAMs), NMRA-861 and NMRA-898, with comprehensive franchise update expected by mid-2026 On-track to report data from Phase 1b study of NMRA-511 in Alzheimer’s disease agitation around</description>
</item>
<item>
<title>Neumora Therapeutics to Participate in Upcoming Conferences in November</title>
<link>https://6ix.com/company/neumora-therapeutics-inc/news/neumora-therapeutics-participate-upcoming-conferences-120000901</link>
<guid isPermaLink="true">https://6ix.com/company/neumora-therapeutics-inc/news/neumora-therapeutics-participate-upcoming-conferences-120000901</guid>
<pubDate>Mon, 03 Nov 2025 12:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in two investor conferences in November. Guggenheim 2nd Annual Healthcare Innovation Conference: Members of management will participate in a fireside chat on Mon</description>
</item>
<item>
<title>Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898</title>
<link>https://6ix.com/company/neumora-therapeutics-inc/news/neumora-therapeutics-announces-initiation-phase-110000575</link>
<guid isPermaLink="true">https://6ix.com/company/neumora-therapeutics-inc/news/neumora-therapeutics-announces-initiation-phase-110000575</guid>
<pubDate>Mon, 27 Oct 2025 11:00:00 GMT</pubDate>
<description>NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora’s M4 franchise; both programs have potential best-in-class pharmacology No convulsions observed in pre-clinical studies conducted in multiple species, including rabbits Neumora plans to provide a comprehensive M4 franchise update by mid-2026 WATERTOWN, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug develop</description>
</item>
<item>
<title>Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model</title>
<link>https://6ix.com/company/neumora-therapeutics-inc/news/neumora-therapeutics-announces-class-leading-103000758</link>
<guid isPermaLink="true">https://6ix.com/company/neumora-therapeutics-inc/news/neumora-therapeutics-announces-class-leading-103000758</guid>
<pubDate>Mon, 27 Oct 2025 10:30:00 GMT</pubDate>
<description>NMRA-215 demonstrated class-leading weight loss of up to 19% as a monotherapy with semaglutide-like induction NMRA-215 demonstrated best-in-class weight loss of up to 26% in combination with semaglutide Class-leading weight loss driven by best-in-class pharmacology and brain penetration of NMRA-215 Neumora plans to initiate Phase 1 clinical study in the first quarter of 2026 WATERTOWN, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmac</description>
</item>
<item>
<title>Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model </title>
<link>https://6ix.com/company/neumora-therapeutics-inc/news/neumora-therapeutics-announces-class-leading-weight-loss-demonstrated-with-nmra-215-in-preclinical-diet-induced-obesity-model</link>
<guid isPermaLink="true">https://6ix.com/company/neumora-therapeutics-inc/news/neumora-therapeutics-announces-class-leading-weight-loss-demonstrated-with-nmra-215-in-preclinical-diet-induced-obesity-model</guid>
<pubDate>Mon, 27 Oct 2025 04:00:00 GMT</pubDate>
<description>NMRA-215 demonstrated class-leading weight loss of up to 19% as a monotherapy with semaglutide-like induction NMRA-215 demonstrated best-in-class weight loss</description>
</item>
<item>
<title>Neumora Therapeutics to Host Virtual R&D Day on October 27</title>
<link>https://6ix.com/company/neumora-therapeutics-inc/news/neumora-therapeutics-host-virtual-r-110000766</link>
<guid isPermaLink="true">https://6ix.com/company/neumora-therapeutics-inc/news/neumora-therapeutics-host-virtual-r-110000766</guid>
<pubDate>Wed, 01 Oct 2025 11:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will host a virtual R&D Day on Monday, October 27, 2025, at 8:00 a.m. ET. Neumora is advancing a robust pipeline of novel mechanisms of action that each have the potential to fun</description>
</item>
<item>
<title>Neumora Therapeutics to Participate in Upcoming Conferences in September</title>
<link>https://6ix.com/company/neumora-therapeutics-inc/news/neumora-therapeutics-participate-upcoming-conferences-110000896</link>
<guid isPermaLink="true">https://6ix.com/company/neumora-therapeutics-inc/news/neumora-therapeutics-participate-upcoming-conferences-110000896</guid>
<pubDate>Tue, 02 Sep 2025 11:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in three investor conferences in September. 2025 Wells Fargo Healthcare Conference: Members of management will be available for one-on-one meetings on Thursday,</description>
</item>
<item>
<title>Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/neumora-therapeutics-inc/news/neumora-therapeutics-reports-second-quarter-200500122</link>
<guid isPermaLink="true">https://6ix.com/company/neumora-therapeutics-inc/news/neumora-therapeutics-reports-second-quarter-200500122</guid>
<pubDate>Wed, 06 Aug 2025 20:05:00 GMT</pubDate>
<description>Initiated Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study with M4 positive allosteric modulator (PAM) NMRA-861, with data expected in the first quarter of 2026 Announces prioritization of obesity as lead indication for NMRA-215, a highly brain-penetrant NLRP3 inhibitor, with data from diet-induced obesity (DIO) mouse model expected in 2025 Entering catalyst-rich period with up to six clinical data readouts in patients over the next 18 months, including Phase 3 data for nava</description>
</item>
<item>
<title>Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025</title>
<link>https://6ix.com/company/neumora-therapeutics-inc/news/neumora-therapeutics-report-second-quarter-110000969</link>
<guid isPermaLink="true">https://6ix.com/company/neumora-therapeutics-inc/news/neumora-therapeutics-report-second-quarter-110000969</guid>
<pubDate>Wed, 23 Jul 2025 11:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including three clinical-stage programs, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Wednesday, August 6, 2025 to report its second quarter 2025 financial results and provide a business update. A live webcast of the event will be available on the</description>
</item>
<item>
<title>Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861</title>
<link>https://6ix.com/company/neumora-therapeutics-inc/news/neumora-therapeutics-announces-initiation-phase-110000109</link>
<guid isPermaLink="true">https://6ix.com/company/neumora-therapeutics-inc/news/neumora-therapeutics-announces-initiation-phase-110000109</guid>
<pubDate>Wed, 09 Jul 2025 11:00:00 GMT</pubDate>
<description>NMRA-861 has potential best-in-class pharmacology, which may enable a more favorable therapeutic profile No convulsions observed in pre-clinical studies conducted in multiple species, including rabbits WATERTOWN, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including three clinical-stage programs, today announced the initiation of a Phase 1 sin</description>
</item>
<item>
<title>Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/neumora-therapeutics-inc/news/neumora-therapeutics-reports-first-quarter-200100293</link>
<guid isPermaLink="true">https://6ix.com/company/neumora-therapeutics-inc/news/neumora-therapeutics-reports-first-quarter-200100293</guid>
<pubDate>Mon, 12 May 2025 20:01:00 GMT</pubDate>
<description>On track to report topline data from NMRA-511 in Alzheimer’s disease agitation around the end of 2025 Resumed enrollment for KOASTAL-3 and -2 studies in March 2025; anticipate reporting topline major depressive disorder data from KOASTAL-3 in the first quarter of 2026 and -2 in the second quarter of 2026 Expect to progress M4 positive allosteric modulator (PAM) program into the clinic in mid-2025 Secured $125 million venture debt facility from K2 HealthVentures, with $40 million available in 202</description>
</item>
<item>
<title>Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025</title>
<link>https://6ix.com/company/neumora-therapeutics-inc/news/neumora-therapeutics-report-first-quarter-110000705</link>
<guid isPermaLink="true">https://6ix.com/company/neumora-therapeutics-inc/news/neumora-therapeutics-report-first-quarter-110000705</guid>
<pubDate>Mon, 28 Apr 2025 11:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including two clinical-stage programs, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Monday, May 12, 2025 to report its first quarter 2025 financial results and provide a business update. A live webcast of the event will be available on the events</description>
</item>
<item>
<title>Neumora Therapeutics to Present at Leerink Global Healthcare Conference</title>
<link>https://6ix.com/company/neumora-therapeutics-inc/news/neumora-therapeutics-present-leerink-global-133000540</link>
<guid isPermaLink="true">https://6ix.com/company/neumora-therapeutics-inc/news/neumora-therapeutics-present-leerink-global-133000540</guid>
<pubDate>Tue, 04 Mar 2025 13:30:00 GMT</pubDate>
<description>WATERTOWN, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced that the Company will present at the Leerink Global Healthcare Conference being held in Miami, FL on Tuesday, March 11, 2025 at 10:00 a.m. ET. A live webcast of the presentation will be available on the Events and Presentations section of the Com</description>
</item>
<item>
<title>Neumora Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/neumora-therapeutics-inc/news/neumora-therapeutics-reports-fourth-quarter-120000142</link>
<guid isPermaLink="true">https://6ix.com/company/neumora-therapeutics-inc/news/neumora-therapeutics-reports-fourth-quarter-120000142</guid>
<pubDate>Mon, 03 Mar 2025 12:00:00 GMT</pubDate>
<description>KOASTAL-2 and -3 studies optimized based on learnings from KOASTAL-1; topline data expected from KOASTAL-3 in the first quarter of 2026 and -2 in the second quarter of 2026 Topline data from NMRA-511 in Alzheimer’s disease agitation expected by the end of 2025 Expect to progress next M4 positive allosteric modulator (PAM) program into the clinic by mid-2025 Strong financial position with $307.6 million in cash, cash equivalents and marketable securities expected to support operations into mid-20</description>
</item>
</channel>
</rss>